Overview

Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain

Status:
Completed
Trial end date:
2019-01-08
Target enrollment:
Participant gender:
Summary
A multi-center, randomized, double-blind, parallel, active-controlled phase III clinical trial to evaluate the efficacy and safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in peripheral neuropathic pain
Phase:
Phase 3
Details
Lead Sponsor:
Daewon Pharmaceutical Co., Ltd.
Treatments:
Pregabalin